PCM
CNCE

Penserra Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Penserra Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-740
Closed -$2K – 1619
2021
Q3 		$2K Buy
740
+10
+1% +$35 ﹤0.01% 1438
2021
Q2 		$3K Hold
730
– – ﹤0.01% 1329
2021
Q1 		$3K Sell
730
-10
-1% -$81 ﹤0.01% 1098
2020
Q4 		$9K Buy
+740
New +$8.44K ﹤0.01% 942

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Penserra Capital Management's CNCE Position: Q4 2021 in Review

Penserra Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 740 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in CNCE in Q4 2020 and held it in 4 quarters. The position peaked at $9K in Q4 2020. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

  • Penserra Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 740 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2K.
  • Penserra Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Concert Pharmaceuticals, Inc. position peaked at $9K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.